Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Neurocrine Biosciences director sells over $297k in stock

Published 2024-05-21, 05:32 p/m
NBIX
-

In recent trading activity, Neurocrine (NASDAQ:NBIX) Biosciences Inc. (NASDAQ:NBIX) Director Richard F. Pops sold 2,100 shares of the company's common stock, as revealed in a regulatory filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $141.84, resulting in a total transaction value exceeding $297,000.

According to the filing, the transactions took place on May 17, 2024, and the shares were sold in multiple transactions at prices ranging from $140.80 to $142.71. This sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Pops on November 21, 2023. Such plans allow company insiders to set up a predetermined schedule for selling stocks at a time when they are not in possession of material non-public information.

The filing also noted that, subsequent to these sales, Pops still owns 31,611 shares of Neurocrine Biosciences, which indicates a continued investment in the company's future. Neurocrine Biosciences, based in San Diego, California, specializes in neurological and endocrine-related diseases and disorders.

Investors often monitor insider sales as they provide insights into how executives view the company's stock value and potential future performance. However, it is important to consider that selling decisions can be influenced by a variety of factors, including personal financial planning and diversification strategies.

For more detailed information, Neurocrine Biosciences and the SEC can provide the specific numbers of shares sold at each price within the range upon request.

InvestingPro Insights

As Neurocrine Biosciences Inc. (NASDAQ:NBIX) makes headlines with insider trading activity, investors are closely examining the company's performance metrics and market position. According to InvestingPro data, Neurocrine Biosciences boasts a robust market capitalization of $14.14 billion, underlining its significant presence in the biotech sector. The company's P/E ratio stands at 37.48, reflecting investor expectations of future earnings growth, which is further supported by a PEG ratio of just 0.08, indicating potential undervaluation based on earnings growth projections.

InvestingPro Tips highlight that Neurocrine Biosciences is expected to see net income growth this year. This aligns with the company's solid revenue growth of nearly 24% over the last twelve months as of Q1 2024. Additionally, the company's stock has experienced a high return over the last year, with a 50.6% price total return, and it is trading near its 52-week high at 94.73% of the peak price. These insights suggest a strong market confidence in the company's performance and future outlook.

For investors seeking to delve deeper into Neurocrine Biosciences' financials and market predictions, there are over 15 additional InvestingPro Tips available, which can be accessed through the following link: https://www.investing.com/pro/NBIX. Interested readers can also take advantage of a special offer using the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing even greater access to valuable market insights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.